Elucidation of the effects of miR-1290 on breast cancer drug resistance

2023 Fiscal Year Final Research Report

• Project/Area Number: 20K17590
• Research Category: Grant-in-Aid for Early-Career Scientists
• Allocation Type: Multi-year Fund
• Review Section: Basic Section 55010:General surgery and pediatric surgery-related
• Research Institution: Nagoya City University
• Principal Investigator: Nishimoto Mayumi 名古屋市立大学, 医薬学総合研究院(医学), 研究員 (00757883)
• Project Period (FY): 2020-04-01 – 2024-03-31
• Keywords: 乳がん / マイクロRNA

Outline of Final Research Achievements

We identified a microRNA, miR-1290, that characterizes breast cancer subtypes. We examined the correlation between secreted miR-1290 expression and breast cancer prognosis and found no significant correlation. In addition, miR-1290 mimics were transfected into breast cancer cell lines, and changes in cell proliferative ability were examined using the WST-1 assay. The correlation between miR-1290 expression and CCND1 was also examined. The higher the expression of miR-1290, the lower the expression of CCND1, but there was no significant correlation with MKI67.

Free Research Field

乳がん

Academic Significance and Societal Importance of the Research Achievements

乳癌の多くを占める、ホルモン受容体陽性乳がんのなかでも、ホルモン療法に感受性の高いものと、やや劣るものが存在する。そのサブタイプの違いに関与すると考えられる分子である、miR-1290というマイクロRNAを同定した。乳癌組織におけるmiR-1290は高発現であると予後良好であったが、血中に分泌される分泌型のmiR-1290は乳がんの予後とは関係ははっきりしなかった。乳がん細胞にmiR-1290を高発現させると、増殖能が低下する傾向が認められた。miR-1290は乳がん治療にとって意義のあるものである可能性がある。